US Approves First Marijuana-Derived Drug
- 40 views
- 0 support
- 5 comments
US regulators on Monday approved the first marijuana-derived drug ever to hit the US market, Epidiolex, which will be used to treat two rare and severe forms of childhood epilepsy.
Epidiolex uses purified cannabidiol, or CBD, which is one of more than 80 active compounds in the cannabis plant. "This is an important medical advance," said US Food and Drug Administration Commissioner Scott Gottlieb. "But it's also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use," he added. "And it was based on well-controlled clinical trials evaluating the use of this compound in the treatment of a specific condition."
The drug is approved for use against Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older, the FDA said. Both forms of epilepsy cause severe seizures. An advisory panel to the FDA recommended in April that the drug be approved. The FDA is not required to follow the advisory panel's advice but usually does.
CBD does not cause intoxication or euphoria. That so-called "high" comes from a different compound in marijuana, known as tetrahydrocannabinol (THC).
What Do You Think About This?
Awesome! It would be better that it be something natural from the earth besides the compounds. I am glad this is getting traction and hope children are really able to benefit from!
I did some research on CBD use for epilepsy, what I found is that the quantity of CBD oil one needs to consume to treat epilepsy is a large amount. And that stuff is not cheap for the amount needed. If anyone has more information on this please let me know.
Anything is better than having a seizure
See the signature
It definitely sucks, but after working a community reach out in the inner city I feel greatful, it could be so much worse.
Give your opinion
Members are also commenting on...
Articles to discover...
02/13/2023 | Advice
11/17/2022 | News
02/14/2022 | News
03/10/2021 | Testimonial
08/29/2018 | News
03/02/2018 | Advice
06/29/2018 | News
02/11/2019 | Advice
You wish to be notified of new comments
You have been subscribed